Create opportunities for physicians who take part in such models voluntarily, and/or other applications that meet designated requirements related to quality improvement, scientific effectiveness, and cost benefits to earn higher improvements. Establish a timetable, to become set by statute, for doctors to begin to transition over several years to the very best models following the period of voluntary adoption and evaluation. Related StoriesStudy finds marked reduction in death, hospitalizations and charges for Medicare patientsNew across-the-board Medicare cuts may place many patients and providers at riskASTRO worried about proposed Medicare doctor payment cuts to radiation therapyThe need for a permanent physician payment option, the ACP notes, offers deep and broad bipartisan support.THE BUSINESS believes that these amendments may address some of the issues raised in the entire Response Letter. The FDA has indicated that A.P. Pharma may incorporate applicable sections of these amendments by particular reference in its resubmission. The Company will be contacting the FDA to demand an End-of-Review conference to discuss the Total Response Letter. A.P. Pharma is committed to expeditiously resolving the rest of the issues required for FDA approval; nevertheless, based on the anticipated time needed to prepare a resubmission, the Company does not anticipate the industrial launch of APF530 this year 2010.